← operator playbook
Apr 14, 20265 min read

Peptides, nutra, and the MCC trap — a survival guide

Peptides and nutraceuticals sit in a permanent MCC gray zone. Here's how the enforcement actually works, what triggers a termination, and what to build on instead.

peptidesnutrapolicy

Peptides and nutra operators live under a specific kind of MCC pressure: they aren't formally banned, they aren't clearly permitted, and the enforcement rules move faster than any operator can adapt.

How the trap works

Card networks classify merchants by MCC. Peptides and research chemicals don't have their own MCC — they get coded as 5122 (drug stores) or 5912 (general pharmacy), depending on how the acquirer categorizes them. Both are legitimate MCCs. Both trigger periodic reviews when the merchant volume grows past thresholds the acquirer doesn't publish.

The trap: an operator's MID is stable at $50k/month. They scale to $500k/month. The acquirer's compliance system flags the volume-vs-MCC mismatch. A review is triggered. During the review, the acquirer requests documentation that the merchant cannot fully produce — because the products don't cleanly fit the MCC they were originally coded as. The account is terminated.

What actually triggers it

  • Volume growth crossing an unpublished threshold — usually somewhere between $250k and $1M monthly.
  • Chargeback ratio drift, even under 1%, when combined with keyword hits in dispute descriptions ('peptide', 'research', 'not FDA approved').
  • A shift in the product mix visible in cart data, if the acquirer pulls it.
  • A regulatory letter to the acquirer about the merchant category, whether or not the specific merchant is named.

What most operators try first, and why it fails

The default reaction is to spread across MIDs. Two MIDs at $250k each look safer than one at $500k. In practice it doubles the operator's exposure — one termination now takes both MIDs down because acquirers share flagged merchant lists. The multi-MID strategy buys weeks, not years.

The second common reaction is to change the MCC. This is fraud. It works until it doesn't, and when it doesn't the merchant loses both the MID and any recourse.

What actually works

The durable pattern for peptides and nutra in 2026:

  1. 01Move the primary rail off cards entirely. Crypto top-ups for repeat customers, cross-rail-verified payment apps for new customers.
  2. 02Keep a card rail for first-time customer acquisition only, at the smallest MID you can maintain in good standing. Accept that this rail will churn every 12–18 months.
  3. 03Structure the business so a card rail termination is a marketing setback, not an existential event. If the majority of your revenue is on rails you control, terminations become manageable.

The operators we work with in these verticals do not treat MCC enforcement as a problem to solve — they treat it as a background weather condition to build around. That framing is what lets them run for years without a payment crisis.

// related reading